Vimarsana
Biggest News Aggregation in the World

Page 3 - Vertice Pharma News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Vertice Pharma. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Vertice Pharma Today - Breaking & Trending Today

Nob Hill Therapeutics Announces Strategic Advisory Board to Accelerate Growth - Vimarsana News

Nob Hill Therapeutics Announces Strategic Advisory Board to Accelerate Growth

Albuquerque, NM (PRWEB) November 22, 2021 -- Nob Hill Therapeutics (NHT) is pleased to announce the members of its Strategic Advisory Board. Under the

Source: prweb.com
COVID Risk in T1D; Lilly to Drop Some Insulin Prices; New ADA/EASD T1D Guideline - Vimarsana News

COVID Risk in T1D; Lilly to Drop Some Insulin Prices; New ADA/EASD T1D Guideline

News and commentary from the endocrinology world

Pharmacokinetic Study Confirming the Bioequivalence of a Novel Oral Solution of Levothyroxine (Thyquidity™) to Synthroid® Presented at The 90th Annual Meeting of the American Thyroid Association - Vimarsana News

Pharmacokinetic Study Confirming the Bioequivalence of a Novel Oral Solution of Levothyroxine (Thyquidity™) to Synthroid® Presented at The 90th Annual Meeting of the American Thyroid Association

/PRNewswire/ -- Vertice Pharma announces the results of a recent study demonstrating the bioequivalence of Thyquidity™, an oral liquid solution of...

US Autoimmune Hemolytic Anemia Drugs Market Size Rising at High CAGR in Forecast Period 2019 to 2028 – KSU - Vimarsana News

US Autoimmune Hemolytic Anemia Drugs Market Size Rising at High CAGR in Forecast Period 2019 to 2028 – KSU

A new research study titled ” US Autoimmune Hemolytic Anemia Drugs market” successfully shows the entire  scenario as well as a comprehensive overview

Afrezza Quarterly Sales Increase, New Therapies on Horizon at MannKind | San Fernando Valley Business Journal - Vimarsana News

Afrezza Quarterly Sales Increase, New Therapies on Horizon at MannKind | San Fernando Valley Business Journal

MannKind Corp. touted increased sales for its flagship drug Afrezza during its fourth quarter earnings report on Thursday, while pointing out its new direction toward therapies for lung and endocrine diseases. During the quarter, MannKind pulled in $10.1 million in revenue for Afrezza, its inhalable insulin, a 30 percent increase compared to sales in the same quarter of 2019. The Westlake Village biotech company reported an adjusted net loss of $13.2 million (-6 cents a share). That’s narrower than the net loss of $14.3 million (-7 cents) in the same period a year earlier. Revenue was $18.4...

Source: sfvbj.com